Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02509507
Title	Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Acronym	MASTERKEY-318
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Amgen
Indications	clear cell renal cell carcinoma breast adenocarcinoma gastroesophageal junction adenocarcinoma hepatocellular carcinoma gastric squamous cell carcinoma colorectal adenocarcinoma melanoma gastric adenocarcinoma lung non-small cell carcinoma
Therapies	Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| DEU \| BEL \| AUT \| AUS